ReviewHuman vaccines & immunotherapeutics2025
Recent developments of vaccines for older adults: Adjuvants and beyond.
Review in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Oropouche Virus (OROV) Vaccine Development for Vulnerable Populations: Epidemiological Context, Challenges and Future Directions.Vaccines · 2026Review
- A review of vaccinology andHuman vaccines & immunotherapeutics · 2025Review
- [Age-associated changes of the immune system: immunosenescence and effects on vaccinations].Zeitschrift fur Gerontologie und Geriatrie · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the global population ages, the development of effective vaccines for older adults has become a public health priority. Immunosenescence, the gradual decline of immune function with age, reduces vaccine efficacy, necessitating novel strategies to enhance immune responses in this population. This review summarizes the current landscape of vaccines for older adults including vaccines against influenza, pneumococcal disease, COVID-19, RSV and herpes zoster and explores recent advancements in vaccines for older adults. Adjuvants can enhance immunogenicity and have played an important role in recent vaccine developments. This review underscores the need for continued innovation to improve existing vaccines, develop vaccines against additional infections including nosocomial pathogens, and to strengthen implementation of vaccination programs to ensure optimal protection against infectious diseases in aging populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.